Brokers Offer Predictions for INKT Q1 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics in a research report issued on Tuesday, March 18th. William Blair analyst M. Phipps forecasts that the company will earn ($0.71) per share for the quarter. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. William Blair also issued estimates for MiNK Therapeutics’ Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.71) EPS and Q4 2026 earnings at ($0.68) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of MiNK Therapeutics in a report on Tuesday.

MiNK Therapeutics Stock Performance

NASDAQ:INKT opened at $7.92 on Thursday. The stock’s fifty day moving average price is $8.91 and its two-hundred day moving average price is $7.75. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $19.00. The company has a market cap of $31.39 million, a price-to-earnings ratio of -2.03 and a beta of 0.16.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12).

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.